1-20 of 25
Sibylle Loibl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials

Paul Jank, Thomas Karn, Marion van Mackelenbergh, Judith Lindner, Denise Treue, Jens Huober, Knut Engels, Christine Solbach, Kurt Diebold, Frederik Marmé, Volkmar Müller, Andreas Schneeweiss, Hans-Peter Sinn, Tanja Fehm, Christian Schem, Elmar Stickeler, Peter Fasching, Jan Budczies, Bärbel Felder, Valentina Nekljudova, Johannes Holtschmidt, Michael Untch, Carsten Denkert, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3868–3880.
https://doi.org/10.1158/1078-0432.CCR-24-0459
Published: 03 September 2024
View article titled, An Analysis of <em>PIK3CA</em> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Open the PDF for An Analysis of <em>PIK3CA</em> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials in another window
Includes: Supplementary data
Journal Articles

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

Theresa Link, Jens-Uwe Blohmer, Wolfgang D. Schmitt, Jan Dominik Kuhlmann, Marianne Just, Michael Untch, Oliver Stotzer, Peter A. Fasching, Marc Thill, Mattea Reinisch, Andreas Schneeweiss, Pauline Wimberger, Sabine Seiler, Jens Huober, Christian Jackisch, Kerstin Rhiem, Claus Hanusch, Bruno V. Sinn, Valentina Nekljudova, Sibylle Loibl, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4606–4612.
https://doi.org/10.1158/1078-0432.CCR-23-1801
Published: 14 November 2023
View article titled, RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial
Open the PDF for RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial in another window
Includes: Supplementary data
Journal Articles

Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features

Hanne Lefrère, Kat Moore, Giuseppe Floris, Joyce Sanders, Iris M. Seignette, Tycho Bismeijer, Dennis Peters, Annegien Broeks, Erik Hooijberg, Kristel Van Calsteren, Patrick Neven, Ellen Warner, Fedro Alessandro Peccatori, Sibylle Loibl, Charlotte Maggen, Sileny N. Han, Katarzyna J. Jerzak, Daniela Annibali, Diether Lambrechts, Karin E. de Visser, Lodewyk Wessels, Liesbeth Lenaerts, Frédéric Amant
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3729–3743.
https://doi.org/10.1158/1078-0432.CCR-22-3645
Published: 15 September 2023
View article titled, Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
Open the PDF for Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features in another window
Includes: Supplementary data
Journal Articles

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

Terence M. Williams, Andreas Schneeweiss, Christian Jackisch, Changxian Shen, Karsten E. Weber, Peter A. Fasching, Carsten Denkert, Jenny Furlanetto, Ernst Heinmöller, Sabine Schmatloch, Thomas Karn, Christopher W. Szeto, Marion T. van Mackelenbergh, Valentina Nekljudova, Elmar Stickeler, Patrick Soon-Shiong, Christian Schem, Thomas Mairinger, Volkmar Müller, Frederik Marme, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3384–3394.
https://doi.org/10.1158/1078-0432.CCR-23-0362
Published: 01 September 2023
View article titled, Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Open the PDF for Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Peter A. Fasching, Christopher Szeto, Carsten Denkert, Stephen Benz, Karsten Weber, Patricia Spilman, Jan Budczies, Andreas Schneeweiss, Elmar Stickeler, Sabine Schmatloch, Christian Jackisch, Thomas Karn, Hans Peter Sinn, Mathias Warm, Marion van Mackelenbergh, Shahrooz Rabizadeh, Christian Schem, Ernst Heinmöller, Volkmar Mueller, Frederik Marmé, Patrick Soon-Shiong, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2456–2465.
https://doi.org/10.1158/1078-0432.CCR-22-2213
Published: 05 July 2023
View article titled, Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Open the PDF for Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer, Jr, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1569–1581.
https://doi.org/10.1158/1078-0432.CCR-22-1989
Published: 14 April 2023
View article titled, Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Open the PDF for Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3433–3442.
https://doi.org/10.1158/1078-0432.CCR-22-0305
Published: 15 August 2022
View article titled, Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Open the PDF for Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study in another window
Includes: Supplementary data
Journal Articles

Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer

Kim R.M. Blenman, Michal Marczyk, Thomas Karn, Tao Qing, Xiaotong Li, Vignesh Gunasekharan, Vesal Yaghoobi, Yalai Bai, Eiman Y. Ibrahim, Tristen Park, Andrea Silber, Denise M. Wolf, Emily Reisenbichler, Carsten Denkert, Bruno V. Sinn, Mariya Rozenblit, Julia Foldi, David L. Rimm, Sibylle Loibl, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2587–2597.
https://doi.org/10.1158/1078-0432.CCR-21-3215
Published: 13 June 2022
View article titled, Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer
Open the PDF for Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

Bruno V. Sinn, Sibylle Loibl, Claus A. Hanusch, Dirk-Michael Zahm, Hans-Peter Sinn, Michael Untch, Karsten Weber, Thomas Karn, Clemens Becker, Frederik Marmé, Wolfgang D. Schmitt, Volkmar Müller, Christian Schem, Denise Treue, Elmar Stickeler, Frederik Klauschen, Nicole Burchardi, Jenny Furlanetto, Marion van Mackelenbergh, Peter A. Fasching, Andreas Schneeweiss, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2584–2591.
https://doi.org/10.1158/1078-0432.CCR-20-3113
Published: 01 May 2021
View article titled, Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Open the PDF for Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial

Karolina Edlund, Katrin Madjar, Antje Lebrecht, Bahriye Aktas, Henryk Pilch, Gerald Hoffmann, Manfred Hofmann, Hans-Christian Kolberg, Daniel Boehm, Marco Battista, Martina Seehase, Kathrin Stewen, Susanne Gebhard, Cristina Cadenas, Rosemarie Marchan, Walburgis Brenner, Annette Hasenburg, Heinz Koelbl, Christine Solbach, Mathias Gehrmann, Berno Tanner, Karsten E. Weber, Sibylle Loibl, Agapios Sachinidis, Jörg Rahnenführer, Marcus Schmidt, Jan G. Hengstler
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2148–2158.
https://doi.org/10.1158/1078-0432.CCR-20-2662
Published: 15 April 2021
View article titled, Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial
Open the PDF for Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial in another window
Includes: Supplementary data
Journal Articles

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

Elena Guerini-Rocco, Kathryn P. Gray, Caterina Fumagalli, Marta Rita Reforgiato, Isabella Leone, Paola Rafaniello Raviele, Elisabetta Munzone, Roswitha Kammler, Patrick Neven, Erika Hitre, Guy Jerusalem, Edda Simoncini, Andrea Gombos, Ines Deleu, Per Karlsson, Stefan Aebi, Jacquie Chirgwin, Vincenzo Di Lauro, Alastair Thompson, Marie-Pascale Graas, Matthew Barber, Christel Fontaine, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Bettina Müller, Seamus O’Reilly, Angelo Di Leo, Aron Goldhirsch, Giuseppe Viale, Massimo Barberis, Meredith M. Regan, Marco Colleoni
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 504–512.
https://doi.org/10.1158/1078-0432.CCR-20-0126
Published: 19 January 2021
View article titled, Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial
Open the PDF for Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial in another window
Includes: Supplementary data
Journal Articles

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Thomas Karn, Tobias Meissner, Karsten E. Weber, Christine Solbach, Carsten Denkert, Knut Engels, Peter A. Fasching, Bruno V. Sinn, Iris Schrader, Jan Budczies, Frederik Marmé, Volkmar Müller, Uwe Holtrich, Bernd Gerber, Christian Schem, Brandon M. Young, Claus Hanusch, Elmar Stickeler, Jens Huober, Marion van Mackelenbergh, Brian Leyland-Jones, Tanja Fehm, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1896–1904.
https://doi.org/10.1158/1078-0432.CCR-19-1954
Published: 15 April 2020
View article titled, A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Open the PDF for A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial in another window
Includes: Supplementary data
Journal Articles

Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

Rina Hui, Alex Pearson, Javier Cortes, Christine Campbell, Camille Poirot, Hatem A. Azim, Jr, Debora Fumagalli, Matteo Lambertini, Fergus Daly, Amal Arahmani, José Perez-Garcia, Philippe Aftimos, Philippe L. Bedard, Laura Xuereb, Elsemieke D. Scheepers, Malou Vicente, Theodora Goulioti, Sibylle Loibl, Sherene Loi, Marie-Jeanne Pierrat, Nicholas C. Turner, Fabrice Andre, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 354–363.
https://doi.org/10.1158/1078-0432.CCR-19-1164
Published: 15 January 2020
View article titled, Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Open the PDF for Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>−</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study in another window
Includes: Supplementary data
Journal Articles

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial

Sibylle Loibl, Denise Treue, Jan Budczies, Karsten Weber, Albrecht Stenzinger, Wolfgang D. Schmitt, Wilko Weichert, Paul Jank, Jenny Furlanetto, Frederick Klauschen, Thomas Karn, Nicole Pfarr, Gunter von Minckwitz, Markus Möbs, Christian Jackisch, Christine Sers, Andreas Schneeweiss, Peter A. Fasching, Christian Schem, Michael Hummel, Marion van Mackelenbergh, Valentina Nekljudova, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3986–3995.
https://doi.org/10.1158/1078-0432.CCR-18-3258
Published: 01 July 2019
View article titled, Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Open the PDF for Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor

Sibylle Loibl, Karsten Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani, Volkmar Müller, Annette Staebler, Gunter von Minckwitz, Ralf Kronenwett, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3358–3365.
https://doi.org/10.1158/1078-0432.CCR-17-2947
Published: 15 July 2018
View article titled, Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Open the PDF for Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor in another window
Includes: Supplementary data
Journal Articles

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial

Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, Valentina Nekljudova, Karsten Weber, Jens Huober, Tanja Fehm, Iris Schrader, Jörn Hilfrich, Frank Holms, Hans Tesch, Christian Schem, Gunter von Minckwitz, Michael Untch, Klaus Pantel
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5384–5393.
https://doi.org/10.1158/1078-0432.CCR-17-0255
Published: 14 September 2017
View article titled, Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Open the PDF for Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial in another window
Includes: Supplementary data
Journal Articles

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Barbara Ingold Heppner, Michael Untch, Carsten Denkert, Berit M. Pfitzner, Bianca Lederer, Wolfgang Schmitt, Holger Eidtmann, Peter A. Fasching, Hans Tesch, Christine Solbach, Mahdi Rezai, Dirk M. Zahm, Frank Holms, Manfred Glados, Petra Krabisch, Esther Heck, Angelika Ober, Petra Lorenz, Kurt Diebold, Jörg-Olaf Habeck, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5747–5754.
https://doi.org/10.1158/1078-0432.CCR-15-2338
Published: 30 November 2016
View article titled, Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Open the PDF for Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

Katrien Berns, Amir Sonnenblick, Annemiek Gennissen, Sylvain Brohée, E. Marielle Hijmans, Bastiaan Evers, Debora Fumagalli, Christine Desmedt, Sibylle Loibl, Carsten Denkert, Patrick Neven, Wei Guo, Fan Zhang, Theo A. Knijnenburg, Tjalling Bosse, Michiel S. van der Heijden, Sanne Hindriksen, Wouter Nijkamp, Lodewyk F.A. Wessels, Heikki Joensuu, Gordon B. Mills, Roderick L. Beijersbergen, Christos Sotiriou, René Bernards
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (21): 5238–5248.
https://doi.org/10.1158/1078-0432.CCR-15-2996
Published: 31 October 2016
View article titled, Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Open the PDF for Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance in another window
Includes: Supplementary data
Journal Articles

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

Sibylle Loibl, Silvia Darb-Esfahani, Jens Huober, Alexander Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gunter von Minckwitz, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (11): 2675–2683.
https://doi.org/10.1158/1078-0432.CCR-15-0965
Published: 31 May 2016
View article titled, Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Open the PDF for Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study

Frederick Klauschen, Stephan Wienert, Wolfgang D. Schmitt, Sibylle Loibl, Bernd Gerber, Jens-Uwe Blohmer, Jens Huober, Thomas Rüdiger, Erhard Erbstößer, Keyur Mehta, Bianca Lederer, Manfred Dietel, Carsten Denkert, Gunter von Minckwitz
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16): 3651–3657.
https://doi.org/10.1158/1078-0432.CCR-14-1283
Published: 13 August 2015
View article titled, Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study
Open the PDF for Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study in another window
Includes: Supplementary data